WCLC 2025: IFITM3 May Improve Immunotherapy Outcomes in SCLC
Interferon-induced transmembrane protein 3 (IFITM3) has been identified as a critical regulator of immunotherapy response in small cell lung cancer (SCLC), with new findings showing its potential role as both a predictive biomarker and therapeutic target.